By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

GW Pharmaceuticals Ltd. 

Porton Down Science Park

Salisbury  Wiltshire  SP4 0JQ  United Kingdom
Phone: 44-1980-619000 Fax: +44-1980-619111


SEARCH JOBS


Industry
Pharmaceutical






Company News
GW Pharmaceuticals To Report Q3 2014 Financial Results And Host Conference Call On 6 August, 2014 7/30/2014 9:08:06 AM
GW Pharmaceuticals Announces The Closing Of U.S. Public Offering Of American Depositary Shares (Adss) Totaling Approximately $169.8 Million On The NASDAQ Global Market And Full Exercise Of Underwriters' Option To Purchase Additional Adss 6/26/2014 7:41:40 AM
GW Pharmaceuticals Eyes $148 Million In NASDAQ Offering 6/19/2014 6:17:37 AM
GW Pharmaceuticals Announces Proposed Public Offering Of ADSs 6/18/2014 8:44:39 AM
GW Pharmaceuticals Announces Physician Reports Of Epidiolex®: Treatment Effect In Children And Young Adults With Treatment-Resistant Epilepsy From Physician-Led Expanded Access Treatment Program 6/17/2014 10:38:10 AM
GW Pharmaceuticals Announces Epidiolex® Receives Fast Track Designation From FDA For The Treatment Of Dravet Syndrome 6/6/2014 9:31:54 AM
GW Pharmaceuticals Announces Agreement With New York State To Investigate Use Of CBD To Treat Medication-Resistant Epilepsies In Children 6/4/2014 12:18:15 PM
GW Pharmaceuticals Receives Investigational New Drug (IND) From FDA For Phase 2/3 Clinical Trial Of Epidiolex® In The Treatment Of Dravet Syndrome 5/7/2014 9:17:17 AM
GW Pharmaceuticals Reports Second Quarter 2014 Financial Results and Operational Progress 5/7/2014 9:01:01 AM
GW Pharmaceuticals Appoints Dr. Kenneth Sommerville As VP, Clinical Science 5/6/2014 9:58:42 AM
12345678910...
//-->